Ligand Acquires Public and Private Companies and Other Assets for $95 Million, Forges Strategic Alliances, and Enters into Many Licensing Arrangements

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) in its acquisitions of CyDex Pharmaceuticals, Inc., Verrow Pharmaceuticals, Inc., Metabasis Therapeutics, Inc. (Nasdaq: MBRX) and Neurogen Corporation (Nasdaq: NRGN); its acquisitions of over 30 third-party royalties/milestone payments streams from Selexis SA; its strategic alliances with Seelos Therapeutics and Nucorion Pharmaceuticals; and over 30 separate licensing arrangements with global and private pharmaceutical companies.

Founded in 1987 as a cutting-edge drug discovery biotech in La Jolla, California, Ligand Pharmaceuticals has built a rich heritage of drug discovery and development innovation.